Unemployed individuals are set to receive weight-loss injections to support their return to employment, as per a new government initiative. The UK’s life sciences sector is poised to benefit from a £279 million investment from the pharmaceutical giant Eli Lilly to develop new medications and treatment delivery methods. Chaired by Amanda Pritchard, Chief Executive of the NHS, weight-loss drugs have been lauded as “game-changers” in aiding individuals to mitigate life-threatening conditions.
Announced during the UK’s International Investment Summit, the collaboration with Eli Lilly includes the inaugural trial of the injection’s impact on unemployment rates, productivity levels, and NHS dependency. According to government officials, obesity ranks as the second most avoidable cause of cancer and significantly contributes to poor health, hindering individuals from fully engaging in the workforce. Health Secretary Wes Streeting emphasised the potential long-term benefits of these medications in revolutionising the approach to tackling obesity.
Currently, obesity rates in England remain stagnant, with 29% of adults classified as obese and 64% overweight or suffering from obesity. This imposes an annual cost of over £11 billion on the NHS, exceeding expenses related to smoking. Excess weight is associated with severe conditions like diabetes, heart attacks, and strokes. Streeting underscored the importance of supporting the UK’s life sciences sector in comprehending obesity further, alongside implementing preventive measures like restricting junk food advertisements, to alleviate strain on the NHS.
The forthcoming trial aims to evaluate the efficacy of tirzepatide, marketed by Eli Lilly as Mounjaro, in weight management. Mounjaro is a weekly injectable pen designed for weight loss, containing tirzepatide to regulate blood sugar levels, energy balance, reduce appetite, and curb cravings. Initially, the medication targets 3,000 obese participants in a five-year study to explore its potential in enhancing productivity and facilitating reentry into the workforce.
Streeting stressed the significance of leveraging the nation’s scientific expertise and NHS resources to advance medical science and benefit patients across the country. As Mounjaro is anticipated to reach around a quarter of a million recipients over the next three years, priority will be given to severe obesity cases with associated health issues. Pritchard echoed similar sentiments, highlighting weight-loss drugs as instrumental in combating public health challenges and reducing risks of critical illnesses.
The initiative is a pivotal step towards positioning the UK as a global leader in life sciences and bringing transformative treatments closer to NHS patients. Streeting emphasised that such partnerships are essential for fostering a healthier society, robust economy, and enhancing the future readiness of the NHS. Pritchard underscored the significance of understanding the benefits of weight management interventions, alongside refining delivery mechanisms in the coming years.